Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Steger, G; Jakesz, R; Singer, C; Dubsky, P; Greil, R.
Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment
BREAST. 2011; 20: S69-S69.St. Gallen .
Doi: 10.1016/S0960-9776(11)70228-4
[Poster]
Web of Science
FullText
FullText_MUG